The cost structure of adagrasib (Krazati) treatment and how to reduce the economic burden of medication

Adagrasib (Krazati) is a KRAS G12C mutation-targeting drug. It is not currently on the market in China, so patients can only rely on overseas channels to purchase drugs. The price of original medicines in the United States is as high as hundreds of thousands of yuan per box, which is very expensive and represents a huge financial expenditure for most patient families. Since the drug usually needs to be taken regularly over a long period of time, the cost of the drug becomes the core and largest part of the expenditure in the entire treatment process, and also directly affects the patient's treatment compliance and long-term efficacy.

In addition to the price of the drug itself, regular imaging examinations, blood biochemistry tests, and liver and kidney function monitoring are required during treatment with adagrasib to evaluate the efficacy and safety of the drug. The cost of these auxiliary examinations will also continue to accumulate as the treatment period prolongs. In addition, some patients may need to combine other supportive treatment drugs during medication, such as antiemetics, liver-protecting drugs, etc., which will also increase the overall treatment cost.

In order to reduce the high cost of treatment, more and more patients are choosing overseas generic drugs that are more affordable. At present, the generic drug of adagrasibu that has been launched in Laos is priced at more than 3,000 yuan per box, and the drug ingredients are consistent with the original drug, and the clinical use experience is also relatively close. For patients who need to take medicine for a long time, the use of generic drugs can reduce the cost of a single box from hundreds of thousands of yuan to several thousand yuan, significantly reducing treatment expenses and allowing more patients to continue to receive targeted therapy.

With the successive introduction of targeted drugs in China, adagrasib is expected to enter the medical insurance catalog through national medical insurance negotiations in the future, and the price is expected to drop further by then. At the same time, patients can also pay attention to charity assistance projects, formal cross-border pharmacies and medical cooperation platforms to find legal and compliant ways to purchase drugs and avoid high-priced channels and the risk of counterfeit drugs. By rationally choosing drug purchasing methods and paying attention to policy changes, patients have the opportunity to significantly reduce the financial pressure of long-term treatment and improve treatment accessibility and quality of life.

Reference materials:https://www.drugs.com/